A guy that thinks AMBS will earn a pathetic $1 Mil
Post# of 30029
AMBS is not undervalued at this point IMHO. They are a company that has a great pipeline that will require many, many millions of dollars to fund and bring their products to the market.
As of this point, we know how they are funding operations, and it isn't shareholder-friendly.
The only reason I haven't sold, besides a substantial flip when GC screwed us in July 2014, is because I have confidence that there will be a substantial amount of money coming from big pharma soon. Whether it be a LymPro partnership or something involving MANF.
Those are my 2015 thoughts on AMBS.